Eliem ends ETX-810 program after unambiguous failure

Eliem Therapeutics (Nasdaq: ELYM), an Anglo-American biotech focused on developing therapies for neuronal excitability disorders, has reported results from its Phase IIa trial investigating ETX-810 for the treatment of lumbosacral radicular pain (LSRP).

ETX-810 is a novel chemical entity prodrug of the bioactive lipid palmitoylethanolamide that was evaluated in two Phase IIa clinical trials, one in subjects with diabetic peripheral neuropathic pain (DPNP) and one in subjects with LSRP.

In the Phase IIa clinical trial in LSRP, ETX-810 did not achieve statistically-significant separation from placebo on the trial’s primary endpoint.